Trillium Therapeutics Inc (TRIL)

[Inoviorulez]

Trillium has both TTI-621 and TTI-622 which are fusion proteins CD47 and because of that they have better features than FTSVs magrolimab.

1.) The first is that TRILS drugs don't bind to red blood cells when they enter the bloodstream at all, on the other hand FTSVs magrolimab does bind to red blood cells causes anemia.

2.) The second is that TRILs drugs being fusion proteins have 2 mechanism of action not only do they offer the blocking of the CD47 "don't eat me" signal, they also boost the "eat me" signal on their own. TTI-621 does a better job of the dual function, TTI-622 is more so the IgG4 extension which doesn't have as strong as linker. That's why Magrolimab being an IgG4 has to be combined with other drugs.

3.) TTI-621 not only is the only anti-CD47 to generate a complete response in cancer, but the company is even thinking of boosting that monotherapy effect by combining it with other immunooncology drugs.

4.) The second generation STING that just got international patents is going to be out-licensed to big pharma, I expect in 1st half 2020 $150 to $200 million in an upfront payment and then $500 million to $700 million in milestone payments.

I state that it will be outlicensed because the company notes it at the end of its presentation and because TRIL has enough cash until 2021. The cash portion is my prediction based on all partnered 1st generation STING agonists programs. I have proof below.

If you see here, Novartis was willing to offer up to $750 million for a working STING product with Aduro biotech. However, the 1st generation STING products haven't lived up.

https://www.fiercebiotech.com/partnering/novartis-tackles-immuno-oncology-a-750m-aduro-deal-for-new-r-d-group

On the flip side, TRIL's STInG is 2nd generation and doesn't have a CDN scaffold like first generation products. That means higher doses, more safety and good anti-tumor activity that can be given either orally or by intravenous infusion.